Hikma’s H1 20 top-line acceleration was driven by COVID-19-related demand in Injectables and Generics and the economic recovery in Algeria propelled growth in the Branded segment. Combined with a favourable product-mix, the operating margin was up 1.5ppt. In the near term, new launches across segments should provide some respite against the ongoing pricing pressure. Given the company’s thin R&D pipeline and a robust balance sheet, M&A (probably in the biosimilars space) se
10 Aug 2020
Milking the COVID-19 opportunities
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Milking the COVID-19 opportunities
Hikma Pharmaceuticals Plc (HIK:LON) | 1,820 18.2 0.1% | Mkt Cap: 4,038m
- Published:
10 Aug 2020 -
Author:
Rishabh Kochar -
Pages:
3
Hikma’s H1 20 top-line acceleration was driven by COVID-19-related demand in Injectables and Generics and the economic recovery in Algeria propelled growth in the Branded segment. Combined with a favourable product-mix, the operating margin was up 1.5ppt. In the near term, new launches across segments should provide some respite against the ongoing pricing pressure. Given the company’s thin R&D pipeline and a robust balance sheet, M&A (probably in the biosimilars space) se